Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001178913-22-001678
Filing Date
2022-04-28
Accepted
2022-04-28 16:04:42
Documents
10
Period of Report
2022-04-28

Document Format Files

Seq Description Document Type Size
1 DEF 14A zk2227688.htm DEF 14A 518187
2 image0.jpg GRAPHIC 1155
3 image1.jpg GRAPHIC 84615
4 image2.jpg GRAPHIC 83922
5 image3.jpg GRAPHIC 13223
6 image4.jpg GRAPHIC 14027
7 image5.jpg GRAPHIC 70529
8 sc2.jpg GRAPHIC 2276
9 sc4.jpg GRAPHIC 5537
10 sc.jpg GRAPHIC 4665
  Complete submission text file 0001178913-22-001678.txt   905526
Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Filer) CIK: 0001534248 (see all company filings)

EIN.: 813676773 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38807 | Film No.: 22866439
SIC: 2834 Pharmaceutical Preparations